These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 2900230)
21. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979 [TBL] [Abstract][Full Text] [Related]
22. P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Pfefferbaum A; Ford JM; White PM; Roth WT Arch Gen Psychiatry; 1989 Nov; 46(11):1035-44. PubMed ID: 2573328 [TBL] [Abstract][Full Text] [Related]
23. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients. Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989 [TBL] [Abstract][Full Text] [Related]
24. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia]. Asato N; Hirayasu Y; Hiramatsu K; Ohta H Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977 [TBL] [Abstract][Full Text] [Related]
25. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771 [TBL] [Abstract][Full Text] [Related]
26. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables. Rein W; Schied HW; Breyer-Pfaff U; Straube E Pharmacopsychiatria; 1983 Sep; 16(5):147-51. PubMed ID: 6140693 [TBL] [Abstract][Full Text] [Related]
27. Auditory event-related potentials and electrodermal activity in medicated and unmedicated schizophrenics. Roth WT; Goodale J; Pfefferbaum A Biol Psychiatry; 1991 Mar; 29(6):585-99. PubMed ID: 1675890 [TBL] [Abstract][Full Text] [Related]
28. Clozapine and electroconvulsive therapy. Fink M Arch Gen Psychiatry; 1990 Mar; 47(3):290-1. PubMed ID: 1968331 [No Abstract] [Full Text] [Related]
29. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol. Nagamoto HT; Adler LE; McRae KA; Huettl P; Cawthra E; Gerhardt G; Hea R; Griffith J Neuropsychobiology; 1999; 39(1):10-7. PubMed ID: 9892854 [TBL] [Abstract][Full Text] [Related]
30. P300 delay and attenuation in schizophrenia: reversal by neuroleptic medication. Coburn KL; Shillcutt SD; Tucker KA; Estes KM; Brin FB; Merai P; Moore NC Biol Psychiatry; 1998 Sep; 44(6):466-74. PubMed ID: 9777178 [TBL] [Abstract][Full Text] [Related]
31. The effects of immediate and short-term retest on the latencies and amplitudes of the auditory event-related potentials in healthy adults. Gandelman-Marton R; Theitler J; Klein C; Rabey JM J Neurosci Methods; 2010 Jan; 186(1):77-80. PubMed ID: 19854216 [TBL] [Abstract][Full Text] [Related]
38. Auditory and visual P300 reflecting cognitive improvement in patients with schizophrenia with quetiapine: a pilot study. Park EJ; Han SI; Jeon YW Prog Neuropsychopharmacol Biol Psychiatry; 2010 May; 34(4):674-80. PubMed ID: 20304022 [TBL] [Abstract][Full Text] [Related]
39. MMN responsivity to manipulations of frequency and duration deviants in chronic, clozapine-treated schizophrenia patients. Horton J; Millar A; Labelle A; Knott VJ Schizophr Res; 2011 Mar; 126(1-3):202-11. PubMed ID: 21194893 [TBL] [Abstract][Full Text] [Related]